CCM Biosciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
CCM Biosciences, Inc. - overview
Established
2019
Location
Mt. Laurel, NJ, US
Primary Industry
Biotechnology
About
Based in Mt. Laurel, US, and founded in 2019, CCM Biosciences, Inc. develops new drugs for different indications and associated companion diagnostic tests. The company was co-founded by Dr.
Anisha Ghosh and Dr. Raj Chakrabarti (CEO). The platforms used for CCM's patented drug development were created at Chakrabarti Advanced Technology. In August 2023, the firm raised USD 25 million in Series A funding from investors.
The company discovers and develops novel drugs, including small molecules, gene therapies, biologics, and nanomedicines. The various platforms of the firm are a small molecule discovery platform, drug delivery platform, biologics discovery platform, and enzyme engineering platform.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals
Website
www.ccm-bio.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.